Answer
Nilotinib binds with high affinity to BCR-ABL’s ATP-binding site, inhibiting its ABL tyrosine kinase activity in Philadelphia chromosome-positive leukaemia cells, with activity against wild-type BCR-ABL and 32/33 imatinib-resistant mutant forms, thereby selectively inhibiting proliferation and inducing apoptosis.
Sources for this answer
- Nilotinib 150mg Hard CapsulesZentiva · emc · SmPC §5.1 Pharmacodynamic properties · Version 2Document updated
Sources checked